Prof Fabrice André speaks to ecancer about the clinical utility of molecular tumour profiling.

He talks about the background of the randomised trial; SAFIR02-BREAST, which aimed to test 2 primary objectives; firstly to see if targeted therapy could improve outcome and secondly whether targeted therapy matched to genomic alterations improved outcome. Prof Andre then explains the methodology and results of this trial and how they had a direct impact on the management of patient’s disease.

Prof Andre concludes by mentioning the impact of these results on the treatment of breast cancer. He says now it is becoming mandatory to add ranking of genomic alterations in genomic report and patients benefit by getting access to molecular tumour profiling technology.